Skip to content

Bioalmanac

VIP

Vasoactive intestinal peptide · Aviptadil (synthetic form)

Clinical trials

Status reviewed 18 Aug 2026

A real human hormone with a real clinical history, including an emergency authorisation attempt during COVID. Its community use for mould illness has no trial behind it at all.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are handled far more than injectables and are correspondingly easier to contaminate.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described nasal protocol50 mcgFour times dailyCommunity practice
Clinical trial administration100–150 mcgContinuous intravenous infusion over 12 hoursClinical trial

When to stop

  • Dizziness, faintness or light-headedness on standing. That is a blood pressure effect.
  • Persistent diarrhoea.
  • Palpitations or chest discomfort.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Not approved in the United States or the European Union. Synthetic VIP (aviptadil) has been through clinical trials including in critical COVID-19, without establishing benefit sufficient for approval. Nasal preparations sold for chronic inflammatory response syndrome are compounded or research-chemical products with no approval for that use.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/vip

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.